[
  {
    "ts": null,
    "headline": "This Is Graco’s Dividend Score After Paying Investors",
    "summary": "Graco just paid investors $0.295 per share on February 4, 2026, marking the company’s 27th consecutive year of quarterly dividend payments. This industrial equipment manufacturer has quietly built one of the more consistent dividend growth records in the specialty machinery sector, with a 5-year compound annual growth rate of approximately 9.4%. But consistency alone doesn’t ... This Is Graco’s Dividend Score After Paying Investors",
    "url": "https://finnhub.io/api/news?id=f5eec16e022d376fe0246cae7b57d34d0cfc9beb584bef3a566290f3c5229468",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770917856,
      "headline": "This Is Graco’s Dividend Score After Paying Investors",
      "id": 139073098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Graco just paid investors $0.295 per share on February 4, 2026, marking the company’s 27th consecutive year of quarterly dividend payments. This industrial equipment manufacturer has quietly built one of the more consistent dividend growth records in the specialty machinery sector, with a 5-year compound annual growth rate of approximately 9.4%. But consistency alone doesn’t ... This Is Graco’s Dividend Score After Paying Investors",
      "url": "https://finnhub.io/api/news?id=f5eec16e022d376fe0246cae7b57d34d0cfc9beb584bef3a566290f3c5229468"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best long-term stocks to invest in for retirement. On February 10, Bernstein SocGen Group reiterated its Market Perform rating and $58 price target on Bristol-Myers Squibb Company (NYSE:BMY) following strong fourth-quarter results, with revenue of $12.5 billion and EPS of $1.26 both beating consensus. The firm highlighted […]",
    "url": "https://finnhub.io/api/news?id=53d1e5f626f5acb6f9ebb18ab963127657b982cd0969eec5a5e9a4807830ee82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770889363,
      "headline": "Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth",
      "id": 139053935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best long-term stocks to invest in for retirement. On February 10, Bernstein SocGen Group reiterated its Market Perform rating and $58 price target on Bristol-Myers Squibb Company (NYSE:BMY) following strong fourth-quarter results, with revenue of $12.5 billion and EPS of $1.26 both beating consensus. The firm highlighted […]",
      "url": "https://finnhub.io/api/news?id=53d1e5f626f5acb6f9ebb18ab963127657b982cd0969eec5a5e9a4807830ee82"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: Still Think It's Dead Money?",
    "summary": "SCHD is benefiting from a rotation out of growth into value and dividend stocks, fueled by expectations of lower interest rates. Read why SCHD ETF is a Buy.",
    "url": "https://finnhub.io/api/news?id=3167929d1cf9f3d0e7931ddd51b6e8b308a753632267460ef5c8c87b016592db",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770885000,
      "headline": "SCHD: Still Think It's Dead Money?",
      "id": 139055217,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210691727/image_1210691727.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "SCHD is benefiting from a rotation out of growth into value and dividend stocks, fueled by expectations of lower interest rates. Read why SCHD ETF is a Buy.",
      "url": "https://finnhub.io/api/news?id=3167929d1cf9f3d0e7931ddd51b6e8b308a753632267460ef5c8c87b016592db"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call",
    "summary": "Bristol-Myers Squibb’s fourth quarter saw continued momentum in its growth portfolio, which management credited as the primary driver behind the company’s positive results. CEO Christopher Boerner highlighted significant contributions from newer products such as Opdualag, Breyanzi, and Camzyos, each surpassing $1 billion in annual sales, and emphasized their early-stage potential. The company also benefited from steady uptake in recently launched therapies, with Reblozyl notably achieving over $",
    "url": "https://finnhub.io/api/news?id=18c942f0f1d1f1900a74e3b40cbd3c11b8efe7ba377bd734298e7d9bedb45f20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770874736,
      "headline": "The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call",
      "id": 139053936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb’s fourth quarter saw continued momentum in its growth portfolio, which management credited as the primary driver behind the company’s positive results. CEO Christopher Boerner highlighted significant contributions from newer products such as Opdualag, Breyanzi, and Camzyos, each surpassing $1 billion in annual sales, and emphasized their early-stage potential. The company also benefited from steady uptake in recently launched therapies, with Reblozyl notably achieving over $",
      "url": "https://finnhub.io/api/news?id=18c942f0f1d1f1900a74e3b40cbd3c11b8efe7ba377bd734298e7d9bedb45f20"
    }
  }
]